Short Term
Mean Reversion
Very Strong
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Very Strong
Momentum
Price
Very Weak
Earnings
Very Weak
Growth
Earnings
Weak
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.8.1300.8133
Address
Fitzroy 425 Smith Street Melbourne, Victoria (VIC) 3065
Description
Dimerix Ltd. engages in the investment of the research and development of biopharmaceutical drugs. It focuses on the development of Dimerix DMX-200 drug candidate in both renal and respiratory indications and the development of Dimerix DMX-700 pre-clinical asset in Chronic Obstructive Pulmonary Disease. The company was founded on May 13, 1975 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.3 - 0.79
Trade Value (12mth)
AU$374,229.00
1 week
-5.3%
1 month
104.29%
YTD
91.95%
1 year
113.43%
All time high
44.74
EPS 3 yr Growth
19.30%
EBITDA Margin
%
Operating Cashflow
-$7m
Free Cash Flow Return
-59.90%
ROIC
-141.00%
Interest Coverage
N/A
Quick Ratio
9.50
Shares on Issue (Fully Dilluted)
555m
HALO Sector
Healthcare
Next Company Report Date
27-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.03
Date | Announcements |
---|---|
08 May 25 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
06 May 25 |
Dimerix receives initial upfront payment from Amicus
×
Dimerix receives initial upfront payment from Amicus |
01 May 25 |
Dimerix Licenses DMX-200 in the US
×
Dimerix Licenses DMX-200 in the US |
01 May 25 |
Investor Webinar and Presentation
×
Investor Webinar and Presentation |
01 May 25 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
30 April 25 |
Quarterly Appendix 4C and Activities Report
×
Quarterly Appendix 4C and Activities Report |
29 April 25 |
Trading Halt
×
Trading Halt |
28 April 25 |
FDA confirms Proteinuria as Primary Endpoint for US approval
×
FDA confirms Proteinuria as Primary Endpoint for US approval |
28 April 25 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
22 April 25 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
16 April 25 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
15 April 25 |
Dimerix to Present at ASX CEO Connect
×
Dimerix to Present at ASX CEO Connect |
10 April 25 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
08 April 25 |
Securities Trading Policy Update
×
Securities Trading Policy Update |
04 April 25 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
02 April 25 |
Dimerix to Present at HealthInvest Summit
×
Dimerix to Present at HealthInvest Summit |
02 April 25 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
28 March 25 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
26 March 25 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
20 March 25 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
14 March 25 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
13 March 25 |
Dimerix to Present at Euroz Hartley Institutional Conference
×
Dimerix to Present at Euroz Hartley Institutional Conference |
12 March 25 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
07 March 25 |
S&P DJI Announces March 2025 Quarterly Rebalance
×
S&P DJI Announces March 2025 Quarterly Rebalance |
06 March 25 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.